NCT01888575

Assessment of Low-dose ASA Discontinuation Risk Associated With Concomitant PPI Use During the First Year of ASA Therapy

Assessment of Low-dose ASA Discontinuation Risk Associated With Concomitant PPI Use During the First Year of ASA Therapy for Secondary Prevention

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 35,604 (actual)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 50 Years – 84 Years
• Healthy volunteers: Not accepted

Summary

This study is conducted in a cohort of low dose aspirin (ASA) users previously ascertained .The aims of the post hoc analyses are: To estimate the one year risk of discontinuation of use of low-dose ASA associated to PPI concomitant use versus non-use, crude and adjusted by confounding. To estimate the one year risk of discontinuation of use of low-dose ASA associated to PPI concomitant use stratified by age and sex. To evaluate other predictors of discontinuation of low-dose ASA during the first year of ASA therapy.

Detailed description

Assessment of low-dose ASA discontinuation risk associated with concomitant PPI use during the first year of ASA therapy for secondary prevention

Conditions

• Cardiovascular Prevention

Interventions

Type	Name	Description
DRUG	Risk of low dose aspirin discontinuation	PPI continuous use; No PPI usePPI

Timeline

• Start date: 2012-09-01
• Primary completion: 2013-06-01
• Completion: 2013-06-01
• First posted: 2013-06-28
• Last updated: 2014-05-13

Locations

1 site across 1 country: Spain